Latest News

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as ...

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Tre

Teva Releases Q3 2025 Aide Memoire

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5,

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement...

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapi...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LA

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine...

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare...

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conf

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic G...

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Trea...

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Reve...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue O

Teva Releases Q2 2025 Aide Memoire

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 3...

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 20

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (frema...

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezum

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-...

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278